SecBot SecBot
PRESS-RELEASE ·Filed May 13, 2026

BWAY

BrainsWay
BULLISH
Impact 8/10
Horizondays Processed6mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ▲ Bullish

The 35% revenue growth, record system shipments, and 25% RPO expansion confirm accelerating adoption. With $58.6M cash and reiterated guidance implying 27-30% full-year growth, the stock should re-rate higher. Watch for FDA clearance for PTSD in MDD (Q2 2026 filing) as a major catalyst.

DirectionBullish
Confidencehigh
Horizondays

How the stock moved after the report

BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$16.31
T+0 close · May 13, 2026 · via day close
Latest settled
−4.97%
T+60 · $15.50
Vs SPY
−9.40%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 13 $16.31entry
  2. T+1 · 6mo ago +0.06%α −0.72% · $16.32
  3. T+5 · 6mo ago −8.71%α −7.55% · $14.89
  4. T+20 · 5mo ago −9.93%α −9.32% · $14.69
  5. T+60 · 3mo ago −4.97%α −9.40% · $15.50
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

BrainsWay reported Q1 2026 revenue of $15.5M (+35% YoY) and net income of $2.3M (+107% YoY), both well above consensus estimates of $14.6M and $0.05 EPS. The company reiterated full-year 2026 guidance of $66-68M revenue and $12-14M Adjusted EBITDA, while shipping a record 117 Deep TMS systems and growing RPOs 25% to $75M.

Key Financial Metrics

EPS
$0.06
est $0.05 · +20.0%
Revenue
$15.5M
est $14.6M · +6.4% · +34.6% YoY
Rating
strong beat
Guidance
$66M-$68M
maintained
Gross Margin
75%

Key Facts

  • Q1 2026 revenue $15.5M, +35% YoY vs $11.5M
  • Net income $2.3M, +107% YoY vs $1.1M
  • GAAP EPS $0.06 vs consensus $0.05 (beat)
  • Adjusted EBITDA $2.8M, +117% YoY
  • Record 117 Deep TMS systems shipped, +44% YoY
  • RPOs $75M, +25% YoY
  • Gross margin 75%, steady YoY
  • Operating income $2.0M vs $0.6M YoY
  • Cash and equivalents $58.6M
  • Reiterated FY2026 guidance: revenue $66-68M, operating income 13-14%, Adjusted EBITDA $12-14M
  • FDA submission planned for PTSD in MDD in Q2 2026
  • First insurer coverage for accelerated SWIFT protocol secured

Financial Impact

Revenue beat by $0.9M (6.2%) vs $14.6M consensus; EPS $0.06 vs $0.05 consensus (20% beat); Adjusted EBITDA doubled to $2.8M

revenueepsadjustedEbitdaoperatingIncomerpo

Risk Factors

  • Reiterated guidance may be conservative given Q1 beat, any future miss would disappoint
  • Investment in Neurolief ($11M total) and BrainStim ($1M) carry execution risk
  • Dependence on expanding insurance coverage for continued growth
  • Cash burn from investing activities ($9.3M in Q1) could pressure balance sheet

Market Snapshot

Exchange
OTC
Sector
Surgical & Medical Instruments & Apparatus
Analyst Consensus
86% bullish (7 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3293884

US Market Status

Market Closed · Opens Wed (11h 54m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 13, 2026